ContraFect Valuation

Is CFRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CFRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CFRX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CFRX's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CFRX?

Key metric: As CFRX is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for CFRX. This is calculated by dividing CFRX's market cap by their current book value.
What is CFRX's PB Ratio?
PB Ratio	-0.1x
Book	-US$5.76m
Market Cap	US$676.12k

CFRX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does CFRX's PB Ratio compare to its peers?

The above table shows the PB ratio for CFRX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	0.3x
BLPH Bellerophon Therapeutics	0.1x	n/a	US$672.8k
SQZB SQZ Biotechnologies	0.4x	n/a	US$737.3k
CAPS Capstone Holding	0.2x	n/a	US$504.4k
VYNT Vyant Bio	0.3x	n/a	US$1.1m
CFRX ContraFect	n/a	n/a	US$676.1k

Price-To-Book vs Peers: CFRX has negative equity and a Price-To-Book Ratio (-0.1x) compared to the peer average (0.3x).

Price to Book Ratio vs Industry

How does CFRX's PB Ratio compare vs other companies in the US Biotechs Industry?

58 Companies	Price / Book	Estimated Growth	Market Cap
GRAL GRAIL	0.2x	35.7%	US$588.01m
AMRN Amarin	0.4x	-7.7%	US$208.43m
IMAB I-Mab	0.4x	1.8%	US$77.50m
MGX Metagenomi	0.3x	-23.2%	US$77.47m

58 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: CFRX has negative equity and a Price-To-Book Ratio (-0.1x) compared to the US Biotechs industry average (1.6x).

Price to Book Ratio vs Fair Ratio

What is CFRX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CFRX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	-0.1x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CFRX's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

BeiGene

US$21.9b

An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.

BGNE

US$206.16

8.2%

10.0%

Collegium Pharmaceutical

US$990.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.71

2.5%

20.0%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.43

-0.2%

-7.1%